{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T18:20:24Z","timestamp":1787854824613,"version":"build-2784847793"},"reference-count":37,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004772","name":"Natural Science Foundation of Ningxia Province","doi-asserted-by":"publisher","award":["2024AAC03776"],"award-info":[{"award-number":["2024AAC03776"]}],"id":[{"id":"10.13039\/501100004772","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cervical cancer (CC) immunotherapy resistance remains a critical clinical challenge. Although immune checkpoint blockade shows efficacy in subsets of patients, the epigenetic and post-transcriptional mechanisms driving resistance are poorly understood. Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1), an m6A \u201creader,\u201d is implicated in tumor progression, but its role in CC immunotherapy resistance is undefined. The aim of this study was to elucidate the function of epigenetic regulator IGF2BP1 and HDAC2 in CC acquired immunotherapy resistance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Multi-omics analysis of GEO\/TCGA datasets identified immunotherapy response related genes. Functional validation employed siRNA knockdown, overexpression, in vitro co-culture assay treated with anti-PD-1. Molecular mechanisms were assessed via RIP\/MeRIP-qPCR, ChIP-qPCR, and luciferase reporter experiments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>IGF2BP1 was significantly upregulated in CC tissues and cell lines (HeLa, SiHa, CaSki, C-33A), correlating with poor survival (P\u2009&lt;\u20090.001). IGF2BP1 knockdown suppressed proliferation and sensitized tumors to anti-PD-1 via enhancing CD8\u2009\u207a\u2009T cell infiltration and IFN\u03b3 secretion. Mechanistically, IGF2BP1 stabilized immune-response genes and stemness program genes (PD-L1, WNT4, POU5F1, MYC) via m6A-dependent mRNA processing. HDAC2 was differentially associated with PD-1 treatment response, suggesting a context-dependent function and potential value as an exploratory biomarker of immunotherapy responsiveness. HDAC2 repressed IGF2BP1 transcription by erasing H3K27ac marks at its promoter. Targeting above axis synergistically enhanced T cells activation and toxic function.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>We unveil an HDAC2\/IGF2BP1\/m6A axis is associated with cervical cancer immunotherapy resistance. HDAC2 loss derepresses IGF2BP1, stabilizing immunosuppressive and stemness-related transcripts via m6A modification. Targeting this axis partially restores PD-1 efficacy, providing a novel insight of cervical cancer immunotherapy resistance.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0355606","type":"journal-article","created":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T17:34:51Z","timestamp":1787852091000},"page":"e0355606","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["HDAC2 restrains IGF2BP1-associated m6A dysregulation in cervical cancer immunotherapy resistance"],"prefix":"10.1371","volume":"21","author":[{"given":"Qiuhong","family":"Deng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jine","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linghua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanxia","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7419-6552","authenticated-orcid":true,"given":"Yongmei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,8,27]]},"reference":[{"key":"pone.0355606.ref001","doi-asserted-by":"crossref","first-page":"1135657","DOI":"10.3389\/fimmu.2023.1135657","article-title":"Cervical cancer immune infiltration microenvironment identification, construction of immune scores, assisting patient prognosis and immunotherapy","volume":"14","author":"S Yao","year":"2023","journal-title":"Front Immunol"},{"issue":"3","key":"pone.0355606.ref002","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1136\/ijgc-2021-002492","article-title":"Advances in immunotherapy for cervical cancer: recent developments and future directions","volume":"32","author":"MV Sherer","year":"2022","journal-title":"Int J Gynecol Cancer"},{"issue":"10316","key":"pone.0355606.ref003","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1016\/S0140-6736(21)02178-4","article-title":"The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study","volume":"398","author":"M Falcaro","year":"2021","journal-title":"Lancet"},{"issue":"3","key":"pone.0355606.ref004","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41571-018-0142-8","article-title":"Cancer immunoediting and resistance to T cell-based immunotherapy","volume":"16","author":"JS O\u2019Donnell","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"pone.0355606.ref005","doi-asserted-by":"crossref","first-page":"975986","DOI":"10.3389\/fimmu.2022.975986","article-title":"Immunotherapy resistance in esophageal cancer: Possible mechanisms and clinical implications","volume":"13","author":"P Fang","year":"2022","journal-title":"Front Immunol"},{"issue":"1","key":"pone.0355606.ref006","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1038\/s41467-024-46769-9","article-title":"Senescence drives immunotherapy resistance by inducing an immunosuppressive tumor microenvironment","volume":"15","author":"D Maggiorani","year":"2024","journal-title":"Nat Commun"},{"issue":"9","key":"pone.0355606.ref007","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/s41577-018-0029-z","article-title":"IFN\u03b3: signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy","volume":"18","author":"LB Ivashkiv","year":"2018","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"pone.0355606.ref008","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.1038\/s41467-022-31764-9","article-title":"Hypoxia induces HIF1\u03b1-dependent epigenetic vulnerability in triple negative breast cancer to confer immune effector dysfunction and resistance to anti-PD-1 immunotherapy","volume":"13","author":"S Ma","year":"2022","journal-title":"Nat Commun"},{"issue":"12","key":"pone.0355606.ref009","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/s41571-022-00689-z","article-title":"Clinical implications of T cell exhaustion for cancer immunotherapy","volume":"19","author":"A Chow","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"issue":"9","key":"pone.0355606.ref010","doi-asserted-by":"crossref","DOI":"10.1016\/j.molcel.2022.02.033","article-title":"Lactylation-driven METTL3-mediated RNA m6A modification promotes immunosuppression of tumor-infiltrating myeloid cells","volume":"82","author":"J Xiong","year":"2022","journal-title":"Mol Cell"},{"issue":"1","key":"pone.0355606.ref011","article-title":"METTL16 drives leukemogenesis and leukemia stem cell self-renewal by reprogramming BCAA metabolism","volume":"30","author":"L Han","year":"2023","journal-title":"Cell Stem Cell"},{"issue":"2","key":"pone.0355606.ref012","doi-asserted-by":"crossref","DOI":"10.1016\/j.stem.2017.11.016","article-title":"METTL14 Inhibits Hematopoietic Stem\/Progenitor Differentiation and Promotes Leukemogenesis via mRNA m6A Modification","volume":"22","author":"H Weng","year":"2018","journal-title":"Cell Stem Cell"},{"issue":"7860","key":"pone.0355606.ref013","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/s41586-021-03536-w","article-title":"Small-molecule inhibition of METTL3 as a strategy against myeloid leukaemia","volume":"593","author":"E Yankova","year":"2021","journal-title":"Nature"},{"issue":"1","key":"pone.0355606.ref014","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41392-020-00450-x","article-title":"The role of m6A modification in the biological functions and diseases","volume":"6","author":"X Jiang","year":"2021","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"pone.0355606.ref015","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41573-025-01280-8","article-title":"RNA modification systems as therapeutic targets","volume":"25","author":"L Zhang","year":"2026","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"pone.0355606.ref016","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41467-022-35710-7","article-title":"Tumor-intrinsic YTHDF1 drives immune evasion and resistance to immune checkpoint inhibitors via promoting MHC-I degradation","volume":"14","author":"W Lin","year":"2023","journal-title":"Nat Commun"},{"issue":"3","key":"pone.0355606.ref017","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/s41556-018-0045-z","article-title":"Recognition of RNA N6-methyladenosine by IGF2BP proteins enhances mRNA stability and translation","volume":"20","author":"H Huang","year":"2018","journal-title":"Nat Cell Biol"},{"issue":"8","key":"pone.0355606.ref018","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/s41419-024-06981-3","article-title":"HDAC2 promotes autophagy-associated HCC malignant progression by transcriptionally activating LAPTM4B","volume":"15","author":"M Wang","year":"2024","journal-title":"Cell Death Dis"},{"issue":"1","key":"pone.0355606.ref019","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1186\/s13046-018-0978-x","article-title":"HDAC2 depletion promotes osteosarcoma\u2019s stemness both in vitro and in vivo: a study on a putative new target for CSCs directed therapy","volume":"37","author":"M La Noce","year":"2018","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"pone.0355606.ref020","doi-asserted-by":"crossref","first-page":"5387","DOI":"10.1038\/s41467-025-60929-5","article-title":"Constitutive expression of the transcriptional co-activator I\u03baB\u03b6 promotes melanoma growth and immunotherapy resistance","volume":"16","author":"A Kolb","year":"2025","journal-title":"Nat Commun"},{"issue":"2","key":"pone.0355606.ref021","doi-asserted-by":"crossref","DOI":"10.1016\/j.stem.2023.12.011","article-title":"Exercise-induced Musclin determines the fate of fibro-adipogenic progenitors to control muscle homeostasis","volume":"31","author":"X Kang","year":"2024","journal-title":"Cell Stem Cell"},{"issue":"18","key":"pone.0355606.ref022","doi-asserted-by":"crossref","first-page":"4953","DOI":"10.1158\/1078-0432.CCR-20-2833","article-title":"Cervical cancer immunotherapy: facts and hopes","volume":"27","author":"L Ferrall","year":"2021","journal-title":"Clin Cancer Res"},{"key":"pone.0355606.ref023","doi-asserted-by":"crossref","first-page":"1105265","DOI":"10.3389\/fimmu.2023.1105265","article-title":"T cell immunotherapy for cervical cancer: challenges and opportunities","volume":"14","author":"L Yu","year":"2023","journal-title":"Front Immunol"},{"issue":"1","key":"pone.0355606.ref024","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1261\/rna.1175909","article-title":"Control of c-myc mRNA stability by IGF2BP1-associated cytoplasmic RNPs","volume":"15","author":"D Weidensdorfer","year":"2009","journal-title":"RNA"},{"issue":"23","key":"pone.0355606.ref025","doi-asserted-by":"crossref","first-page":"4340","DOI":"10.1158\/0008-5472.CAN-22-1289","article-title":"MNX1-AS1 Promotes Phase Separation of IGF2BP1 to Drive c-Myc-Mediated Cell-Cycle Progression and Proliferation in Lung Cancer","volume":"82","author":"Q Zhu","year":"2022","journal-title":"Cancer Res"},{"issue":"1","key":"pone.0355606.ref026","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1038\/s41467-023-37542-5","article-title":"PRMT3-mediated arginine methylation of IGF2BP1 promotes oxaliplatin resistance in liver cancer","volume":"14","author":"Y Shi","year":"2023","journal-title":"Nat Commun"},{"issue":"1","key":"pone.0355606.ref027","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/s41467-020-20527-z","article-title":"circNDUFB2 inhibits non-small cell lung cancer progression via destabilizing IGF2BPs and activating anti-tumor immunity","volume":"12","author":"B Li","year":"2021","journal-title":"Nat Commun"},{"key":"pone.0355606.ref028","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/s41577-019-0264-y","article-title":"The importance of exosomal PDL1 in tumour immune evasion","volume":"20","author":"D Daassi","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"pone.0355606.ref029","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.immuni.2024.02.007","article-title":"CD4(+) T cell activation distinguishes response to anti-PD-L1+anti-CTLA4 therapy from anti-PD-L1 monotherapy","volume":"57","author":"A Franken","year":"2024","journal-title":"Immunity"},{"issue":"9","key":"pone.0355606.ref030","doi-asserted-by":"crossref","DOI":"10.1016\/j.immuni.2024.08.003","article-title":"PD-1 signaling limits expression of phospholipid phosphatase 1 and promotes intratumoral CD8+ T cell ferroptosis","volume":"57","author":"Y Ping","year":"2024","journal-title":"Immunity"},{"key":"pone.0355606.ref031","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.molcel.2024.01.024","article-title":"UFL1 ablation in T cells suppresses PD-1 UFMylation to enhance anti-tumor immunity","volume":"84","author":"C He","year":"2024","journal-title":"Mol Cell"},{"key":"pone.0355606.ref032","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.ccell.2020.09.001","article-title":"The PD-1\/PD-L1-Checkpoint Restrains T cell Immunity in Tumor-Draining Lymph Nodes","volume":"38","author":"F Dammeijer","year":"2020","journal-title":"Cancer Cell"},{"issue":"4","key":"pone.0355606.ref033","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/sj.cdd.4401567","article-title":"Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1\/WAF1 expression, independent of histone deacetylase 1","volume":"12","author":"BH Huang","year":"2005","journal-title":"Cell Death Differ"},{"issue":"19","key":"pone.0355606.ref034","doi-asserted-by":"crossref","first-page":"3261","DOI":"10.1007\/s00018-011-0628-3","article-title":"HDAC2 and TXNL1 distinguish aneuploid from diploid colorectal cancers","volume":"68","author":"T Gemoll","year":"2011","journal-title":"Cell Mol Life Sci"},{"issue":"1","key":"pone.0355606.ref035","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.1038\/s41467-025-58350-z","article-title":"Structural mimicry of UM171 and neomorphic cancer mutants co-opts E3 ligase KBTBD4 for HDAC1\/2 recruitment","volume":"16","author":"Z Chen","year":"2025","journal-title":"Nat Commun"},{"issue":"1","key":"pone.0355606.ref036","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41419-025-07477-4","article-title":"HAT1\/HDAC2 mediated ACSL4 acetylation confers radiosensitivity by inducing ferroptosis in nasopharyngeal carcinoma","volume":"16","author":"P Zhou","year":"2025","journal-title":"Cell Death Dis"},{"key":"pone.0355606.ref037","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1038\/s41375-025-02584-9","article-title":"HDAC1 acts as a tumor suppressor in ALK-positive anaplastic large cell lymphoma: implications for HDAC inhibitor therapy","volume":"39","author":"M Zrim\u0161ek","year":"2025","journal-title":"Leukemia"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0355606","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T17:34:57Z","timestamp":1787852097000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0355606"}},"subtitle":[],"editor":[{"given":"Kangkang","family":"Ji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,8,27]]},"references-count":37,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8,27]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0355606","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,27]]}}}